# A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia

> **NCT00088621** · PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Lurasidone 80mg tablet

## Key facts

- **NCT ID:** NCT00088621
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2014-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088621, "A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00088621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*